Innovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial

Reuters

Jul 17

<a href="https://laohu8.com/S/IVBXF">Innovent Biologics</a> Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial

Innovent Biologics, Inc. has announced the publication of results from a Phase 1 clinical study of its anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The study results, published in Nature Medicine, demonstrate clinical potential and highlight the therapy's recognition in the international academic community. The successful completion of this study has led to the initiation of a multi-regional Phase 3 clinical trial, G-HOPE-001, in 2024, to further assess the safety and efficacy of IBI343. Innovent Biologics is also investigating the potential applications of IBI343 in treating pancreatic cancer and other diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31609) on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2552176586"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552176586\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552176586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552176586","market":"fut","top_or_hot":-1,"title":"Innovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics</a> Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Innovent Biologics, Inc. has announced the publication of results from a Phase 1 clinical study of its anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The study results, published in Nature Medicine, demonstrate clinical potential and highlight the therapy's recognition in the international academic community. The successful completion of this study has led to the initiation of a multi-regional Phase 3 clinical trial, G-HOPE-001, in 2024, to further assess the safety and efficacy of IBI343. Innovent Biologics is also investigating the potential applications of IBI343 in treating pancreatic cancer and other diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31609) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics</a> Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Innovent Biologics, Inc. has announced the publication of results from a Phase 1 clinical study of its anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The study results, published in Nature Medicine, demonstrate clinical potential and highlight the therapy's recognition in the international academic community. The successful completion of this study has led to the initiation of a multi-regional Phase 3 clinical trial, G-HOPE-001, in 2024, to further assess the safety and efficacy of IBI343. Innovent Biologics is also investigating the potential applications of IBI343 in treating pancreatic cancer and other diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31609) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL2xZSxd:1","article_id":"2552176586","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552176586","pubTimestamp":1752710425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial. Innovent Biologics, Inc. has announced the publication of results from a Phase 1 clinical study of its anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The study results, published in Nature Medicine, demonstrate clinical potential and highlight the therapy's recognition in the international academic community. The successful completion of this study has led to the initiation of a multi-regional Phase 3 clinical trial, G-HOPE-001, in 2024, to further assess the safety and efficacy of IBI343. Innovent Biologics is also investigating the potential applications of IBI343 in treating pancreatic cancer and other diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01801":"信达生物","BK1161":"生物科技","BK1147":"投资银行业与经纪业","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","01911":"华兴资本控股","BK1583":"高瓴概念"},"translate_title":"信达生物宣布发表创新抗CLDN18.2 ADC 1期临床研究结果，启动全球3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"Innovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial\n    \n\n        Innovent Biologics, Inc. has announced the publication of results from a Phase 1 clinical study of its anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma. The study results, published in Nature Medicine, demonstrate clinical potential and highlight the therapy's recognition in the international academic community. The successful completion of this study has led to the initiation of a multi-regional Phase 3 clinical trial, G-HOPE-001, in 2024, to further assess the safety and efficacy of IBI343. Innovent Biologics is also investigating the potential applications of IBI343 in treating pancreatic cancer and other diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN31609) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}